Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention

Cardiology Clinics

Volumn 29, Issue 1, 2011, Pages 137-156

  Vijayaraghavan, Krishnaswami ^a,b   Deedwania, Prakash ^c  

^a Scottsdale Healthcare   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Cardiovascular disease; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANRENONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; EPROSARTAN; FOSINOPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; REMIKIREN; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; UNINDEXED DRUG; ZOFENOPRIL;

ABSENCE OF SIDE EFFECTS; ACUTE HEART INFARCTION; ADD ON THERAPY; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IC 50; INSULIN RESISTANCE; KIDNEY DISEASE; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STROKE; VASCULAR ENDOTHELIUM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 78751635214     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.11.003     Document Type: Review

References (114)

1. Tigerstedt R., Bergman P. Niere und Kreislauf. Skand Arch Physiol 1898, 8:223-271.
2. Braun-Menendez E., Page I.H. Suggested revision of nomenclature-angiotensin. Science 1958, 127:242.
3. Page I.H., Helmer O.M. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med 1940, 71:29-42.
4. Skeggs L.T., Lentz K.E., Kahn J.R., et al. The amino acid sequence of hypertensin. II. J Exp Med 1956, 104:193-197.
5. Kageyama R., Ohkubo H., Nakanishi S. Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence. Biochemistry 1984, 23:3603-3609.
6. Braun-Menendez E., Fasciolo J.C., Leloir L.F., et al. The substance causing renal hypertension. J Physiol 1940, 98:283-298.
7. Skeggs L.T., Kahn J.R., Lentz K., et al. The existence of two forms of hypertensin. J Exp Med 1957, 99:275-282.
8. Skeggs L.T., Kahn J.R., Lentz K., et al. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957, 106:439-453.
9. Davis J.O. Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism. Recent Prog Horm Res 1959, 17:293-352.
10. Hedner T., Hansson L., Himmelmann A. The renin-angiotensin system-a century of progress. Blood Press 1998, 7:68-70.
11. Hackenthal E., Paul M., Ganten D., et al. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 1990, 70:1067-1116.
12. Persson P.B., Skalweit A., Thiele B.J. Controlling the release and production of renin. Acta Physiol Scand 2004, 181:375-381.
13. Johnston C.I., Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997, 10:306S-310S.
14. 2 receptors. Blood Press 1996, 5(Suppl 2):47-52.
15. Quinn S.J., Williams G.H. Regulation of aldosterone secretion. Annu Rev Physiol 1988, 50:409-426.
16. Timmermans P.B., Wong P.C., Chiu A.T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251.
17. Unger T., Culman J., Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998, 16(Suppl 7):S3-S9.
18. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747-803.
19. Bühler F.R., Bolli P., Kiowski W., et al. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984, 77:36-42.
20. Redgrave J., Rabinowe S., Hollenberg N.K., et al. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 1985, 75:1285-1290.
21. Bachmann S., Peters J., Engler E., et al. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int 1992, 41:24-36.
22. Vaney C., Waeber B., Turini G., et al. Renin and the complications of acute myocardial infarction. Chest 1984, 86:40-43.
23. Remes J. Neuroendocrine activation after myocardial infarction. Br Heart J 1994, 72:S65-S69.
24. Isnard R., Pousset F., Trochu J., et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000, 86:417-421.
25. Perondi R., Saino A., Tio R.A., et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992, 85:2004-2013.
26. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994, 90:2056-2069.
27. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
28. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
29. Francis G.S., Goldsmith S.R., Levine T.B., et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984, 101:370-377.
30. Dzau V.J. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987, 31:1402.
31. Kawano H., Do Y.S., Kawano Y., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130-1137.
32. Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000, 32:865-879.
33. Britten M.B., Zeiher A.M., Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999, 245:315-327.
34. Diet F., Pratt R.E., Berry G.J., et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756-2767.
35. Brown N.J., Agirbasli M.A., Williams G.H., et al. Effect of activation and inhibition of the rennin-angiotensin system on plasma PAI-1. Hypertension 1998, 32:965-971.
36. Moule K.S., Denton R.M. Multiple signaling pathways involved in the metabolic effects of insulin. Am J Cardiol 1997, 80(3):41A-49A.
37. Nascimben L., Bothwell J.H., Dominguez D.Y., et al. Angiotensin II stimulates insulin-independent glucose uptake in hypertrophied rat hearts [abstract]. J Hypertens 1997, 15(Suppl 4):S84.
38. Schorb W., Peeler T.C., Madigan N.N., et al. Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat. J Biol Chem 1994, 269:19626-19632.
39. Wan J., Kurosaki T., Huant X.Y., et al. Tyrosine kinases in activation of the MAP-kinase cascade by G protein-coupled receptors. Nature 1996, 380:541-544.
40. Saad M.J.A., Velloso L.A., Carvalho C.R. Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 1995, 310:741-744.
41. Bernobich E., de Angelis L., Lerin C., et al. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 2002, 62(9):1295-1314.
42. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
43. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999, 354:1751-1756.
44. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000, 342:145-153.
45. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
46. Gueyffier F., Bulpitt C., Boissel J.P., et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA group. Lancet 1999, 353:793-796.
47. Bulpitt C.J., Beckett N.S., Cooke J., et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003, 21:2409-2417.
48. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887-1898.
49. Braunwald E., Domanski M.J., Fowler S.E., et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058-2068.
50. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995, 345:669-685.
51. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 1996, 27:337-344.
52. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
53. Swedberg K., Held P., Kjekshus J., et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992, 327:678-684.
54. Rutherford J.D., Pfeffer M.A., Moye L.A., et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE investigators. Circulation 1994, 90:1731-1738.
55. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study group. N Engl J Med 1995, 333:1670-1676.
56. Torp-Pedersen C., Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril cardiac evaluation. Lancet 1995, 354:9-12.
57. Cleland J.G., Erhardt L., Murray G., et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study investigators. Eur Heart J 1997, 18:41-51.
58. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) study investigators. N Engl J Med 1995, 332:80-85.
59. Pitt B., O'Neill B., Feldman R., QUIET Study Group, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001, 87:1058-1063.
60. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998, 97:2202-2212.
61. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575-1581.
62. Latini R., Tognoni G., Maggioni A.P., et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-Converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000, 35:1801-1807.
63. Rodrigues E.J., Eisenberg M.J., Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003, 115:473-479.
64. Al-Mallah M.H., Tleyjeh I.M., Abdel-Latif A.A., et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006, 47:1576-1583.
65. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 1991, 325:293-302.
66. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
67. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
68. Carson P., Ziesche S., Johnson G., et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5:178-187.
69. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
70. Bosch J., Yusuf S., Pogue J., et al. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002, 324:699-702.
71. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
72. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
73. Dickstein K., Kjekshus J., OPTIMAAL Steering Committee of the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002, 360:752-760.
74. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
75. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752.
76. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
77. Granger C.B., Ertl G., Kuch J., et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000, 139:609-617.
78. Konstam M.A., Neaton J.D., Dickstein K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374:1840-1848.
79. Lee V.C., Rhew D.C., Dylan M., et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004, 141:693-704.
80. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
81. Yusuf S., Teo K., Anderson C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-1183.
82. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
83. Schrader J., Lüders S., Kulschewski A., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 6:1218-1226.
84. Yusuf S., Diener H.C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-1237.
85. Ennezat P.V., Berlowitz M., Sonnenblick E.H., et al. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000, 2:258-262.
86. Balcells E., Meng Q.C., Johnson W.H., et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.
87. Brown J.D., Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007, 115:518-533.
88. Doulton T.W., He F.J., MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45:880-886.
89. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
90. Campbell N.R., Khan N.A., Hill M.D., et al. 2009 Canadian Hypertension Education Program recommendations: the scientific summary-an annual update. Can J Cardiol 2009, 25:271-277.
91. Phillips C.O., Kashani A., Ko D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007, 167:1930-1936.
92. Jennings D.L., Kalus J.S., Coleman C.I., et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007, 24:486-493.
93. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
94. Fried L.F., Duckworth W., Zhang J.H., et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4:361-368.
95. McMurray J.J., Holman R.R., Haffner S.M., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. NAVIGATOR Study Group. N Engl J Med 2010, 362(16):1477-1490.
96. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 19:2388-2442.
97. Ezekowitz J.A., McAlister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009, 30:469-477.
98. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
99. Atlas S.A. The Renin-Angiotensin Aldosterone System: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007, 13:S9-S20.
100. Piepho R.W., Beal J. An overview of antihypertensive therapy in the 20th century. J Clin Pharmacol 2000, 40:967-977.
101. Pool J.L. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007, 13:21-33.
102. Buczko W., Hermanowicz J.M. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008, 60:623-631.
103. Kelly D.J., Wilkinson-Berka J.L., Gilbert R.E. Renin inhibition: new potential for an old therapeutic target. Hypertension 2005, 46:569-576.
104. Staessen J.A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006, 368:1449-1456.
105. Wood J.M., Schnell C.R., Cumin F., et al. Aliskiren: a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005, 23:417-426.
106. Gradman A.H., Schmieder R.E., Lins R.L., et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
107. Oparil S., Yarows S.A., Patel S., et al. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007, 370:1126-1127.
108. Andersen K., Weinberger M.H., Egan B., et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008, 26:589-599.
109. McMurray J.J.V., Pitt B., Latini R., Aliskiren Observation of Heart Failure Treatment, I, et al. effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17-24.
110. Ingelfinger J.R. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 2008, 358:2503-2505.
111. Parving H.H., Persson F., Lewis J.B., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. Nat Clin Pract Nephrol 2008, 4:656-657.
112. Parving H.H., Brenner B.M., McMurray J.J., et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009, 24:1663-1671.
113. Solomon S.D., Appelbaum E., Manning W.J., et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530-537.
114. Daniel A.D., Pamela D., Jaco B. The AGELESS Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients ≥65 years of age with systolic hypertension. Circulation 2008, 118:S886-S887.